Deals Of The Week: Shire/arGEN-X/Ethris, Evotec/Yale, Amgen/Bind Biosciences
Executive Summary
GSK’s venture arm outlines its investment priorities, which involve changes to the biopharma business model.
You may also be interested in...
Evotec Drug Development Strategy Offers Little Downside, Big Upside
Germany’s Evotec hopes to evolve into an integrated multi-service biopharma company through its three-pronged business strategy comprising a high-growth drug-discovery business, a series of pipeline options that pose no financial obligation for the biotech, and a growing list of scientific collaborations that offer potential long-term value.
Ultragenyx Takes On Rare Childhood Disease With In-licensing Deal
Rare disease company Ultragenyx has in-licensed the North American rights to a treatment for fatty-acid oxidation disorder, adding its third clinical-stage drug to its ultra-rare disease pipeline.
Shire Adds To HGT Unit With Lotus Acquisition; Gets Preclinical Rare Disease Treatment
Shire makes a bolt-on acquisition that will complement both its rare disease franchise and its regenerative medicines unit.